These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33854064)

  • 41. Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections.
    Kim J; Pai H; Seo MR; Kang JO
    BMC Infect Dis; 2012 May; 12():109. PubMed ID: 22571633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study.
    Schechner V; Fallach N; Braun T; Temkin E; Carmeli Y
    J Antimicrob Chemother; 2021 Jul; 76(8):2182-2185. PubMed ID: 33969419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection.
    Cho Y; Park K; Park J; An J; Myung H; Yoon H
    Int J Antimicrob Agents; 2024 Aug; 64(2):107222. PubMed ID: 38810936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bacteriophage endolysins as a potential weapon to combat
    Mondal SI; Draper LA; Ross RP; Hill C
    Gut Microbes; 2020 Nov; 12(1):1813533. PubMed ID: 32985336
    [No Abstract]   [Full Text] [Related]  

  • 45. Risk factors for colonization with multidrug-resistant Gram-negative bacteria and
    Azzini AM; Be G; Naso L; Lambertenghi L; Salerno ND; Coledan I; Bazaj A; Mirandola M; Miotti J; Mazzaferri F; Accordini S; Lo Cascio G; Tacconelli E
    Front Cell Infect Microbiol; 2023; 13():1155320. PubMed ID: 37377644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
    Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
    Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data.
    Liu Y; Dai M; Zhang K; Zhang L; Lin B; Chen K; Wang H; Gu Z; Yu Y; Wang Y
    Int J Antimicrob Agents; 2024 Oct; 64(4):107288. PubMed ID: 39089342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ridinilazole: a novel therapy for Clostridium difficile infection.
    Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
    Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis.
    Paschos P; Ioakim K; Malandris K; Koukoufiki A; Nayfeh T; Akriviadis E; Tsapas A; Bekiari E
    Anaerobe; 2021 Oct; 71():102441. PubMed ID: 34454094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
    Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
    Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment.
    Pakpour S; Bhanvadia A; Zhu R; Amarnani A; Gibbons SM; Gurry T; Alm EJ; Martello LA
    Microbiome; 2017 Nov; 5(1):148. PubMed ID: 29132405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis.
    Lee AA; Rao K; Limsrivilai J; Gillilland M; Malamet B; Briggs E; Young VB; Higgins PDR
    Inflamm Bowel Dis; 2020 Oct; 26(11):1748-1758. PubMed ID: 31971239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clostridioides difficile Biofilm.
    Vuotto C; Donelli G; Buckley A; Chilton C
    Adv Exp Med Biol; 2024; 1435():249-272. PubMed ID: 38175479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical predictors of recurrent Clostridium difficile infection in out-patients.
    Shivashankar R; Khanna S; Kammer PP; Scott Harmsen W; Zinsmeister AR; Baddour LM; Pardi DS
    Aliment Pharmacol Ther; 2014 Sep; 40(5):518-22. PubMed ID: 25039269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care.
    Khanafer N; Touré A; Chambrier C; Cour M; Reverdy ME; Argaud L; Vanhems P
    World J Gastroenterol; 2013 Nov; 19(44):8034-41. PubMed ID: 24307797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.
    Cui Y; Zhang C; Jia Q; Gong X; Tan Y; Hua X; Jian W; Yang S; Hayer K; Raja Idris RK; Zhang Y; Wu Y; Tu Z
    BMC Infect Dis; 2023 Oct; 23(1):703. PubMed ID: 37858038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.
    Adelman MW; Goodenough D; Sefton S; Mackey C; Thomas S; Fridkin SK; Woodworth MH
    Anaerobe; 2021 Aug; 70():102364. PubMed ID: 33862203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Collateral damage": antibiotics and the risk of Clostridium difficile infection.
    Yam FK; Smith KM
    Orthopedics; 2005 Mar; 28(3):275-9. PubMed ID: 15790086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
    McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
    Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.